A Clinical Study Comparing Restylane® Silk and Belotero Balance® for the Treatment of Superficial, Vertical Perioral Lines

Inclusion Criteria: * Patients exhibiting moderate \[2\] to severe \[3\] superficial, vertical perioral lines on the 5-point Merz® validated scale for assessment of superficial perioral lines * Females and males in good general health over the age of 18 years old Must be willing to give and sign a HIPAA form, informed consent form and a photographic release form * Patient is planning to undergo Restylane® Silk and Belotero Balance® injections * For female patient of childbearing potential, must have had a regular menstrual cycle prior to study entry (a female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation) and is willing to use an acceptable form of birth control during the entire course of the study \[i.e., acceptable methods of birth control are oral contraceptives, contraceptive patches/rings/implants Norplanit®, Depo-Provena®, double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies of partner with a documented second acceptable method of birth control should the patient become sexually active\]. All systemic birth control measures must be in consistent use at least 30 days prior to study participation * Negative urine pregnancy test results at the time of study entry (if applicable) * Must be willing to comply with study regimen and complete the entire course of the study. Exclusion Criteria: * A patient with any uncontrolled systemic disease. A potential patient in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study A patient with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study. * A patient with a known hypersensitivity to any of the components of the study medications * A patient who is actively smoking or plans to smoke at any time of the duration of this study * A patient with an active skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis, herpes labialis) * A patient planning any other cosmetic procedure to their facial area during the study period, other than the treatments that will be performed by the investigator * A patient using any topical (prescription or over the counter) medicated creams, lotions, gels, balms, powders, etc. on the treatment areas during the study period * A patient receiving any topical products containing alpha-hydroxy acids, salicylic acid, and vitamins C or D (includes derivatives thereof) on the perioral areas within 7 days prior to or during the study period, other than the study products * A patient receiving any investigational drug and/or has had a microdermabrasion (light or medium skin peel) treatment on their perioral areas within 30 days prior to or during the study period * A patient using any topical tretinoin product or derivative on their perioral areas within 12 weeks prior to or during the study period * A patient receiving a chemical peel, any systemic steroids, a non-ablative laser, light or radio frequency treatment and/or has had a dermabrasion (deep skin peel) or ablative laser treatments on their perioral areas must have discontinued the drug/treatment and/or had the procedure at least 6 months prior to entering the study * A patient that has previously been treated with botulinum toxin in the perioral areas within the past six months * A patient that has previously been treated with dermal filler in the perioral areas within the past year * A patient that with a history of allergic reaction to a dermal filler or lidocaine * A patient that with a history of a permanent filler to the perioral areas * A female patient who is pregnant, nursing an infant or planning a pregnancy during the study \[throughout the course of the study, women of child-bearing potential must use reliable forms of contraception (i.e., oral contraceptive, intrauterine device, abstinence, or spermicides and condoms used in combination)\] * Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.